DOCSLIB.ORG

SACGHS Report on Gene Patents And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SACGHS Report on Gene Patents And Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests Report of the Secretary’s Advisory Committee on Genetics, Health, and Society April 2010 A pdf version of this report is available at http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_patents_report_2010.pdf Secretary’s Advisory Committee on Genetics, Health, and Society 6705 Rockledge Drive Suite 750, MSC 7985 Bethesda, MD 20892-7985 301-496-9838 (Phone) 301-496-9839 (Fax) http://www4.od.nih.gov/oba/sacghs.htm March 31, 2010 The Honorable Kathleen Sebelius Secretary of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201 Dear Secretary Sebelius: In keeping with our mandate to provide advice on the broad range of policy issues raised by the development and use of genetic technologies as well as our charge to examine the impact of gene patents and licensing practices on access to genetic testing, the Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS) is providing to you its report Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests. The report explores the effects of patents and licensing practices on basic genetic research, genetic test development, patient access to genetic tests, and genetic testing quality and offers advice on how to address harms and potential future problems that the Committee identified. It is based on evidence gathered through a literature review and original case studies of genetic testing for 10 clinical conditions as well as consultations with experts and a consideration of public perspectives. Based on its study, SACGHS found that patents on genetic discoveries do not appear to be necessary for either basic genetic research or the development of available genetic tests. The Committee also found that patents have been used to narrow or clear the market of existing tests, thereby limiting, rather than promoting availability of testing. SACGHS found that patients have been unable to obtain testing when a patent-protected sole provider does not accept particular payers, particularly state Medicaid insurance. SACGHS also found that when there is a patent- enforcing sole provider, patients cannot obtain independent second-opinion testing, and sample sharing as a means of ensuring the quality of testing is not possible. The substantial number of existing patents on genes and methods of diagnosis also pose a threat to the development of multiplex testing, parallel sequencing, and whole-genome sequencing, the areas of genetic testing with the greatest potential future benefits. The six recommendations contained in this report identify steps that the Department of Health and Human Services could take to help address existing harms and to help eliminate potential barriers to development of promising new testing technologies. The statutory changes the Committee has proposed are narrowly tailored to directly address the identified problems without altering patent rights for therapeutics. We appreciate the opportunity to serve you and the Department and hope the report will help you and the Department in achieving equitable access to health care and stimulating progress in health care technology. Sincerely, Steven Teutsch, M.D., M.P.H. SACGHS Chair SACGHS ROSTER Chair Steven Teutsch, M.D., M.P.H. (2010)* David Dale, M.D. (2012) Chief Science Officer Professor of Medicine Los Angeles County Department of Health University of Washington 313 North Figueroa Street 1959 NE Pacific Street Los Angeles, CA 90012 Seattle, WA 98195 Members Gwen Darien (2012) Executive Director Mara Aspinall, M.B.A. (2011) Samuel Waxman Cancer Research Foundation President and CEO 1249 Fifth Avenue, Suite 907 On-Q-ity New York, NY 10029 610 Lincoln Street Waltham, MA 02451 Rochelle Dreyfuss, M.S., J.D. (2011) Pauline Newman Professor of Law Sylvia Mann Au, M.S., CGC (2010)** New York University School of Law Hawaii State Genetics Coordinator 40 Washington Square South Genetics Program New York, NY 10012-1099 Hawaii Department of Health 741 Sunset Avenue Charis Eng, M.D., Ph.D. (2013) Honolulu, HI 96816 Chair and Founding Director Genomic Medical Institute Janice V. Bach, M.S. (2013) Cleveland Clinic Foundation State Genetics Coordinator and Manager 9500 Euclid Avenue Michigan Department of Community Health Cleveland, OH 44195 Genomic and Genetic Disorders Section 201 Townsend Street James P. Evans, M.D., Ph.D. (2010) Lansing, MI 48909 Professor of Genetics and Medicine Director of Clinical Cancer Genetics and the Paul Billings, M.D., Ph.D., FACP, FACMG Bryson Program in Human Genetics (2011) Departments of Medicine and Genetics Director and Chief Scientific Officer The University of North Carolina at Chapel Hill Genomic Medicine Institute Chapel Hill, NC 27599 El Camino Hospital Mountain View, CA 94040 Andrea Ferreira-Gonzalez, Ph.D. (2010) Professor of Pathology and Director of Molecular Diagnostics Laboratory Virginia Commonwealth University 403 North 13th Street Richmond, VA 23298 * The year indicates the year in which the member’s term expires. ** Term ended following the February 2010 SACGHS meeting. i Julio Licinio, M.D. (2010)** Director The John Curtin School of Medical Research The Australian National University Canberra, ACT 2601 Acton, Australia Barbara Burns McGrath, R.N., Ph.D. (2010) Research Associate Professor School of Nursing University of Washington Box 357263 Seattle, WA 98195 Samuel Nussbaum, M.D. (2012) Executive Vice President Clinical Health Policy and Chief Medical Officer Wellpoint 120 Monument Circle Indianapolis, IN 46204 Charmaine D. M. Royal, Ph.D. (2012) Associate Research Professor Institute for Genome Sciences and Policy Duke University Box 91009 450 Research Drive Durham, NC 27708 Sheila Walcoff, J.D (2012) Partner McDermott, Will & Emery, LLP 600 13th Street, NW, Suite 1200 Washington, DC 20005 Marc S. Williams, M.D., FAAP, FACMG (2010) Director Intermountain Healthcare Clinical Genetics Institute 324 10th Avenue Salt Lake City, UT 84103 Paul Wise, M.D., M.P.H. (2011) Richard E. Behrman Professor of Child Health and Society CHP/PCOR Stanford University 117 Encina Commons Stanford, CA 94305 * The year indicates the year in which the member’s term expires. ** Term ended following the February 2010 SACGHS meeting. ii Ex Officio Members Muin J. Khoury, M.D., Ph.D. Director Department of Commerce Office of Public Health Genomics Centers for Disease Control and Prevention Michael Amos, Ph.D. 1825 Century Center Boulevard Scientific Advisor Atlanta, GA 30345 Chemical Science and Technology Laboratory National Institute of Standards and Technology Jeffrey Roche, M.D. 100 Bureau Drive Medical Officer Gaithersburg, MD 20899 Office of Clinical Standards and Quality Centers for Medicare & Medicaid Services Department of Defense MS S3-02-01 7500 Security Boulevard LTC Adam Kanis, MC, USA Baltimore, MD 21244 Department of Pediatrics Tripler Army Medical Center Alberto Gutierrez, Ph.D. MCHK-PE Deputy Director 1 Jarrett White Road Office of In Vitro Diagnostic Device Evaluation Tripler AMC (Honolulu), HI 96859 and Safety Center for Devices and Radiological Health Department of Energy Food and Drug Administration 2098 Gaither Road Daniel Drell, Ph.D. Rockville, MD 20850 Biologist Life Sciences Division Denise Geolot, Ph.D., R.N. Office of Biological and Environmental Director Research Center for Quality 1000 Independence Avenue, SW Health Resources and Services Administration Washington, DC 20585 5700 Fishers Lane Rockville, MD 20857 Department of Health and Human Services Eric Green, M.D., Ph.D. Naomi Goldstein, Ph.D. Director Director National Human Genome Research Institute Office of Planning, Research, and Evaluation MSC 2152 Administration for Children and Families 31 Center Drive 370 L’Enfant Promenade, SW Bethesda, MD 20892 Washington, DC 20447 Robinsue Frohboese, J.D., Ph.D. Gurvaneet Randhawa, M.D., M.P.H Principal Deputy Director Medical Officer Office for Civil Rights Center for Outcomes and Evidence (COE) 200 Independence Avenue, SW Agency for Healthcare Research & Quality Washington, DC 20201 540 Gaither Road Rockville, MD 20850 Michael A. Carome, M.D. Associate Director for Regulatory Affairs Office for Human Research Protections 1101 Wootton Parkway, Suite 200 Rockville, MD 20852 iii Department of Labor Phyllis Borzi, J.D., M.A. Assistant Secretary of Labor Employee Benefits Security Administration 200 Constitution Avenue, NW, Suite S-2524 Washington, DC 20210 Department of Veterans Affairs Ellen Fox, M.D. Director National Center for Ethics in Health Care 810 Vermont Avenue, NW Washington, DC 20420 Equal Employment Opportunity Commission Stuart Ishimaru, J.D. Acting Chair 1801 L Street, NW Washington, DC 20507 Federal Trade Commission Sarah Botha, J.D. Attorney Division of Advertising Practices Bureau of Consumer Protection 600 Pennsylvania Avenue, NW Washington, D.C. 20580 iv ACKNOWLEDGMENTS The Committee wishes to thank the members of the SACGHS Task Force on Gene Patents and Licensing Practices, which served from October 2006 to September 2009, for their assistance in the development of this report. The Task Force was chaired by James Evans and included the following SACGHS members: Mara Aspinall, who served on it before becoming a Committee member and then continued as a Member, Rochelle Dreyfuss, and Andrea Ferreira-Gonzalez. The Task Force also included former SACGHS members Chira Chen, a patient representative; Joseph Telfair, a public health and consumer advocacy expert; Sylvia Au, a state genetics program coordinator; Debra
Load more

Recommended publications
  • Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide
    BASIC RESEARCH www.jasn.org Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide Onur Cil, Peter M. Haggie, Puay-wah Phuan, Joseph-Anthony Tan, and Alan S. Verkman Departments of Medicine and Physiology, University of California San Francisco, San Francisco, California ABSTRACT 2 2 Pendrin is a Cl /HCO3 exchanger expressed in type B and non-A, non-B intercalated cells in the distal 2 nephron, where it facilitates Cl absorption and is involved in Na+ absorption and acid-base balance. Pendrin-knockout mice show no fluid-electrolyte abnormalities under baseline conditions, although mice 2 with double knockout of pendrin and the Na+/Cl cotransporter (NCC) manifest profound salt wasting. Thus, pendrin may attenuate diuretic-induced salt loss, but this function remains unconfirmed. To clarify the physiologic role of pendrin under conditions not confounded by gene knockout, and to test the potential utility of pendrin inhibitors for diuretic therapy, we tested in mice a small-molecule pendrin inhibitor identified from a high-throughput screen. In vitro, a pyrazole-thiophenesulfonamide, PDSinh- 2 C01, inhibited Cl /anion exchange mediated by mouse pendrin with a 50% inhibitory concentration of 1–3 mM, without affecting other major kidney tubule transporters. Administration of PDSinh-C01 to mice at predicted therapeutic doses, determined from serum and urine pharmacokinetics, did not affect urine output, osmolality, salt excretion, or acid-base balance. However, in mice treated acutely with furosemide, + 2 administration of PDSinh-C01 produced a 30% increase in urine output, with increased Na and Cl ex- cretion. In mice treated long term with furosemide, in which renal pendrin is upregulated, PDSinh-C01 produced a 60% increase in urine output.
    [Show full text]
  • Iron Transport Proteins: Gateways of Cellular and Systemic Iron Homeostasis
    Iron transport proteins: Gateways of cellular and systemic iron homeostasis Mitchell D. Knutson, PhD University of Florida Essential Vocabulary Fe Heme Membrane Transport DMT1 FLVCR Ferroportin HRG1 Mitoferrin Nramp1 ZIP14 Serum Transport Transferrin Transferrin receptor 1 Cytosolic Transport PCBP1, PCBP2 Timeline of identification in mammalian iron transport Year Protein Original Publications 1947 Transferrin Laurell and Ingelman, Acta Chem Scand 1959 Transferrin receptor 1 Jandl et al., J Clin Invest 1997 DMT1 Gunshin et al., Nature; Fleming et al. Nature Genet. 1999 Nramp1 Barton et al., J Leukocyt Biol 2000 Ferroportin Donovan et al., Nature; McKie et al., Cell; Abboud et al. J. Biol Chem 2004 FLVCR Quigley et al., Cell 2006 Mitoferrin Shaw et al., Nature 2006 ZIP14 Liuzzi et al., Proc Natl Acad Sci USA 2008 PCBP1, PCBP2 Shi et al., Science 2013 HRG1 White et al., Cell Metab DMT1 (SLC11A2) • Divalent metal-ion transporter-1 • Former names: Nramp2, DCT1 Fleming et al. Nat Genet, 1997; Gunshin et al., Nature 1997 • Mediates uptake of Fe2+, Mn2+, Cd2+ • H+ coupled transporter (cotransporter, symporter) • Main roles: • intestinal iron absorption Illing et al. JBC, 2012 • iron assimilation by erythroid cells DMT1 (SLC11A2) Yanatori et al. BMC Cell Biology 2010 • 4 different isoforms: 557 – 590 a.a. (hDMT1) Hubert & Hentze, PNAS, 2002 • Function similarly in iron transport • Differ in tissue/subcellular distribution and regulation • Regulated by iron: transcriptionally (via HIF2α) post-transcriptionally (via IRE) IRE = Iron-Responsive Element Enterocyte Lumen DMT1 Fe2+ Fe2+ Portal blood Enterocyte Lumen DMT1 Fe2+ Fe2+ Fe2+ Fe2+ Ferroportin Portal blood Ferroportin (SLC40A1) • Only known mammalian iron exporter Donovan et al., Nature 2000; McKie et al., Cell 2000; Abboud et al.
    [Show full text]
  • Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)
    BRIEF COMMUNICATION www.jasn.org Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytropic Retroviral Receptor in the Nephron Camille Ansermet,* Matthias B. Moor,* Gabriel Centeno,* Muriel Auberson,* † † ‡ Dorothy Zhang Hu, Roland Baron, Svetlana Nikolaeva,* Barbara Haenzi,* | Natalya Katanaeva,* Ivan Gautschi,* Vladimir Katanaev,*§ Samuel Rotman, Robert Koesters,¶ †† Laurent Schild,* Sylvain Pradervand,** Olivier Bonny,* and Dmitri Firsov* BRIEF COMMUNICATION *Department of Pharmacology and Toxicology and **Genomic Technologies Facility, University of Lausanne, Lausanne, Switzerland; †Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts; ‡Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia; §School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; |Services of Pathology and ††Nephrology, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland; and ¶Université Pierre et Marie Curie, Paris, France ABSTRACT Tight control of extracellular and intracellular inorganic phosphate (Pi) levels is crit- leaves.4 Most recently, Legati et al. have ical to most biochemical and physiologic processes. Urinary Pi is freely filtered at the shown an association between genetic kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical polymorphisms in Xpr1 and primary fa- sodium-dependent phosphate transporters, NaPi-IIa/NaPi-IIc/Pit2. However, the milial brain calcification disorder.5 How- molecular identity of the protein(s) participating in the basolateral Pi efflux remains ever, the role of XPR1 in the maintenance unknown. Evidence has suggested that xenotropic and polytropic retroviral recep- of Pi homeostasis remains unknown. Here, tor 1 (XPR1) might be involved in this process. Here, we show that conditional in- we addressed this issue in mice deficient for activation of Xpr1 in the renal tubule in mice resulted in impaired renal Pi Xpr1 in the nephron.
    [Show full text]
  • Primary Liver Cancer: Epidemiological And
    PRIMARY LIVER CANCER: EPIDEMIOLOGICAL AND BIOMARKER DISCOVERY STUDIES Nimzing Gwamzhi Ladep Imperial College London Department of Medicine December 2013 Thesis submitted for Doctor of Philosophy 1 THESIS ABSTRACT With previous reports indicating changes in mortality, risk factors and management of primary liver cancer (PLC), evaluation of current trends in the incidence and mortality rates was indicated. Late diagnosis has been implicated to be a major contributor to the high fatality rates of PLC. This work aimed at: studying trends of PLC by subcategories globally in general, and in England and Wales, in particular; investigating liver-related morbidities of HIV infected patients in an African setting; and discovering urinary biomarkers of hepatocellular carcinoma. The World Health Organisation (WHO) and Small Area Health Statistics Unit (SAHSU) databases were interrogated respectively, in order to achieve the first aim. The second aim was achieved through utilisation of databases of an African-based HIV treatment programme- AIDS Prevention Initiative in Nigeria (APIN), located in Jos, Nigeria. The European Union-funded Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) case-control study in three West African countries was the platform through which urinary metabolic profiling was accomplished. Proton nuclear magnetic resonance spectroscopy (NMR) and parallel ultra-performance liquid chromatography mass spectrometry (UPLC-MS) were used for biomarker discovery studies. Mortality rates of intrahepatic bile duct carcinoma (IHBD) increased in all countries that were studied. Misclassification of hilar cholangiocarcinoma accounted for only a small increase in the rate of IHBD in England and Wales. With over 90% screening rate for viral hepatitides, the rates of hepatitis B (HBV), hepatitis C (HCV) and 2 HBV/HCV in HIV-infected patients in the APIN programme were 17.8%, 11.3% and 2.5% respectively.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • HER Inhibitor Promotes BRAF/MEK Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Harboring BRAFV600E
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 12), pp: 19843-19854 Research Paper HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E Lingxiao Cheng1,*, Yuchen Jin1,*, Min Liu1, Maomei Ruan2, Libo Chen1 1Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China 2Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China *Co-first authors Correspondence to: Libo Chen, email: [email protected] Keywords: papillary thyroid cancer, redifferentiation, iodine, glucose, dabrafenib Received: October 20, 2016 Accepted: January 24, 2017 Published: February 28, 2017 ABSTRACT Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HER3 is a resistance mechanism, and combination with HER inhibitor to prevent MAPK rebound may sensitize BRAFV600E- mutant thyroid cancer cells to redifferentiation therapy. To evaluate if inhibiting both BRAF/MEK and HER can produce stronger redifferetiation effect, we tested the effects of BRAF/MEK inhibitor dabrafenib/selumetinib alone or in combination with HER inhibitor lapatinib on the expression and function of iodine- and glucose-handling genes in BRAFV600E-positive BCPAP and K1 cells, using BHP 2-7 cells harboring RET/ PTC1 rearrangement as control. Herein, we showed that lapatinib prevented MAPK rebound and sensitized BRAFV600E-positive papillary thyroid cancer cells to BRAF/ MEK inhibitors. Dabrafenib/selumetinib alone increased iodine-uptake and toxicity and suppressed glucose-metablism in BRAFV600E-positive papillary thyroid cancer cells.
    [Show full text]
  • Development of the Stria Vascularis and Potassium Regulation in the Human Fetal Cochlea: Insights Into Hereditary Sensorineural Hearing Loss
    Development of the Stria Vascularis and Potassium Regulation in the Human Fetal Cochlea: Insights into Hereditary Sensorineural Hearing Loss Heiko Locher,1,2 John C.M.J. de Groot,2 Liesbeth van Iperen,1 Margriet A. Huisman,2 Johan H.M. Frijns,2 Susana M. Chuva de Sousa Lopes1,3 1 Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, 2333 ZA, the Netherlands 2 Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, 2333 ZA, the Netherlands 3 Department for Reproductive Medicine, Ghent University Hospital, 9000 Ghent, Belgium Received 25 August 2014; revised 2 February 2015; accepted 2 February 2015 ABSTRACT: Sensorineural hearing loss (SNHL) is dynamics of key potassium-regulating proteins. At W12, one of the most common congenital disorders in humans, MITF1/SOX101/KIT1 neural-crest-derived melano- afflicting one in every thousand newborns. The majority cytes migrated into the cochlea and penetrated the base- is of heritable origin and can be divided in syndromic ment membrane of the lateral wall epithelium, and nonsyndromic forms. Knowledge of the expression developing into the intermediate cells of the stria vascula- profile of affected genes in the human fetal cochlea is lim- ris. These melanocytes tightly integrated with Na1/K1- ited, and as many of the gene mutations causing SNHL ATPase-positive marginal cells, which started to express likely affect the stria vascularis or cochlear potassium KCNQ1 in their apical membrane at W16. At W18, homeostasis (both essential to hearing), a better insight KCNJ10 and gap junction proteins GJB2/CX26 and into the embryological development of this organ is GJB6/CX30 were expressed in the cells in the outer sul- needed to understand SNHL etiologies.
    [Show full text]
  • Ferredoxin Reductase Is Critical for P53-Dependent Tumor Suppression Via Iron Regulatory Protein 2
    Downloaded from genesdev.cshlp.org on October 11, 2021 - Published by Cold Spring Harbor Laboratory Press Ferredoxin reductase is critical for p53- dependent tumor suppression via iron regulatory protein 2 Yanhong Zhang,1,9 Yingjuan Qian,1,2,9 Jin Zhang,1 Wensheng Yan,1 Yong-Sam Jung,1,2 Mingyi Chen,3 Eric Huang,4 Kent Lloyd,5 Yuyou Duan,6 Jian Wang,7 Gang Liu,8 and Xinbin Chen1 1Comparative Oncology Laboratory, Schools of Veterinary Medicine and Medicine, University of California at Davis, Davis, California 95616, USA; 2College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210014, China; 3Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; 4Department of Pathology, School of Medicine, University of California at Davis Health, Sacramento, California 95817, USA; 5Department of Surgery, School of Medicine, University of California at Davis Health, Sacramento, California 95817, USA; 6Department of Dermatology and Internal Medicine, University of California at Davis Health, Sacramento, California 95616, USA; 7Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan 48201 USA; 8Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA Ferredoxin reductase (FDXR), a target of p53, modulates p53-dependent apoptosis and is necessary for steroido- genesis and biogenesis of iron–sulfur clusters. To determine the biological function of FDXR, we generated a Fdxr- deficient mouse model and found that loss of Fdxr led to embryonic lethality potentially due to iron overload in developing embryos. Interestingly, mice heterozygous in Fdxr had a short life span and were prone to spontaneous tumors and liver abnormalities, including steatosis, hepatitis, and hepatocellular carcinoma.
    [Show full text]
  • Association Between Hereditary Hemochromatosis and Hepatocellular Carcinoma: a Comprehensive Review
    Jayachandran et al. Hepatoma Res 2020;6:8 Hepatoma Research DOI: 10.20517/2394-5079.2019.35 Review Open Access Association between hereditary hemochromatosis and hepatocellular carcinoma: a comprehensive review Aparna Jayachandran1,2, Ritu Shrestha1,2, Kim R. Bridle1,2, Darrell H. G. Crawford1,2 1The University of Queensland, Faculty of Medicine, Brisbane, QLD 4006, Australia. 2Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia. Correspondence to: Prof. Darrell H. G. Crawford, Gallipoli Medical Research Institute, The University of Queensland, Faculty of Medicine, Lower Lobby Level, Administration Building, Greenslopes Private Hospital, Greenslopes, QLD 4120, Australia. E-mail: [email protected] How to cite this article: Jayachandran A, Shrestha R, Bridle KR, Crawford DHG. Association between hereditary hemochromatosis and HCC: a comprehensive review. Hepatoma Res 2020;6:8. http://dx.doi.org/10.20517/2394-5079.2019.35 Received: 15 Nov 2019 First Decision: 10 Dec 2019 Revised: 4 Feb 2020 Accepted: 18 Feb 2020 Published: 6 Mar 2020 Science Editor: Guang-Wen Cao Copy Editor: Jing-Wen Zhang Production Editor: Tian Zhang Abstract Hepatocellular carcinoma (HCC) is a significant global health problem with high morbidity and mortality. Its incidence is increasing exponentially worldwide with a close overlap between annual incidence and death rates. Even though significant advances have been made in HCC treatment, fewer than 20% of patients with HCC are suitable for potentially curative treatment. Hereditary hemochromatosis (HH) is an important genetic risk factor for HCC. HH is an autosomal recessive disorder of iron metabolism, characterised by elevated iron deposition in most organs including the liver, leading to progressive organ dysfunction.
    [Show full text]
  • Secondary Hemochromatosis As a Result of Acute Transfusion-Induced Iron Overload in a Burn Patient Michael Amatto1 and Hernish Acharya2*
    Amatto and Acharya Burns & Trauma (2016) 4:10 DOI 10.1186/s41038-016-0034-z CASE REPORT Open Access Secondary hemochromatosis as a result of acute transfusion-induced iron overload in a burn patient Michael Amatto1 and Hernish Acharya2* Abstract Background: Red blood cell transfusions are critical in burn management. The subsequent iron overload that can occur from this treatment can lead to secondary hemochromatosis with multi-organ damage. Case Presentation: While well recognized in patients receiving chronic transfusions, we present a case outlining the acute development of hemochromatosis secondary to multiple transfusions in a burn patient. Conclusions: Simple screening laboratory measures and treatment options exist which may significantly reduce morbidity; thus, we believe awareness of secondary hemochromatosis in those treating burn patients is critical. Keywords: Secondary hemochromatosis, Transfusion, Iron overload, Burn patients Background of parental iron or RBC transfusions, neonatal iron over- Acute and chronic treatment of the severely burned indi- load, aceruloplasminemia, and African iron overload [6, 7]. vidual is often complex due to many physical and psycho- Hemochromatosis is a disease characterized by iron logical factors [1, 2]. Resuscitation involving packed red accumulation in tissues. Initial symptoms and signs in- blood cell (RBC) transfusion is often essential [3]. How- clude skin pigmentation, fatigue, erectile dysfunction, ever, RBC transfusion carries potential risks including and arthralgia while later stages of the disease result in hemolytic reactions and infections, as well as other com- cardiomyopathy, diabetes mellitus, hypogonadism, hypo- plications that are often overlooked such as iron overload pituitarism, and hypoparathyroidism, as well as liver fi- [4, 5]. Each unit of RBCs contains 200–250 mg of iron, brosis and cirrhosis which can lead to hepatocellular and with no physiologic excretion mechanism, multiple carcinoma [6].
    [Show full text]
  • Nr EC Aandoening Orphacode Patiëntenorganisatie Vragenlijst
    Nr EC Aandoening Orphacode Patiëntenorganisatie Vragenlijst P PNR ingediend? G-24-12 ABeta amyloidosis, Dutch type ORPHA:100006 Vereniging HCHWA-D Nee P 14 G-8-7 Tubular duplication of the esophagus ORPHA:100048 Vereniging voor Ouderen en Kinderen met Slokdarmafsluiting (VOKS) Ja P 124 G-17-10 Neurogenic thoracic outlet syndrome ORPHA:100073 RSI-vereniging Nee P 305 G-11-43 Laryngeal neuroendocrine tumor ORPHA:100083 St NET-Groep Ja P 62 G-11-43 Middle ear neuroendocrine tumor ORPHA:100084 St NET-Groep Ja P 62 G-11-1 Thyroid tumor ORPHA:100087 Schildklier Organisatie NL (SON) Ja P 60 G-11-13 Thyroid tumor ORPHA:100087 Schildklier Organisatie NL (SON) Ja P 60 G-11-35 Thyroid Tumor ORPHA:100087 Schildklier Organisatie NL (SON) Ja P 60 G-11-13 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-11-35 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-3-11 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-3-17 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-3-13 Adrenal/paraganglial tumor ORPHA:100091 Nlse Vereniging voor patiënten met Paragangliomen (NVPG) Ja P 29 G-3-13 Adrenal/paraganglial tumor ORPHA:100091 Bijniervereniging (NVACP) Nee P 64 G-3-2 Adrenal/paraganglial tumor ORPHA:100091 Nlse Vereniging voor Patiënten met Paragangliomen (NVPG) Ja P 29 G-3-2 Adrenal/paraganglial tumor ORPHA:100091 Bijniervereniging (NVACP) Nee P 64 G-11-29 Gastroenteropancreatic neuroendocrine neoplasm ORPHA:100092 St NET-Groep Ja P 62 G-11-27 Thymic tumor ORPHA:100100
    [Show full text]